Australia Legalizes Medicinal Use of Certain Psychedelics

MDMA and psilocybin used for therapy will be reclassified by July 1, 2023.

The Australian government has signaled a new direction for the country’s view on psychedelics to treat certain mental health conditions.

The Therapeutic Goods Administration (TGA) will reschedule medicines containing psilocybin and MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression.

The decision allows for the compounds to be used therapeutically in a controlled medical setting by authorized psychiatrists.

Psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) used for therapy will be reclassified as Schedule 8 (controlled drugs) medicines by July 1, 2023. The two will remain in Schedule 9 (prohibited substances) for all other uses, restricting supply to clinical trials.

“The decision acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses,” the agency wrote in a Feb. 3 statement. “It means that psilocybin and MDMA can be used therapeutically in a controlled medical setting. However, patients may be vulnerable during psychedelic-assisted psychotherapy, requiring controls to protect these patients.”

The decision follows applications made to the TGA to reclassify the substances in the Poisons Standard, extensive public consultation, a report from an expert panel, as well as advice received from the Advisory Committee on Medicines Scheduling.

There are currently no approved products containing MDMA or psilocybin that the agency has evaluated for quality, safety, and efficacy.

“This amendment will allow authorized psychiatrists to access and legally supply a specified ’unapproved’ medicine containing these substances to patients under their care for these specific uses,” the agency said.

Philip J. Young, chairman and CEO of Vancouver-based psychedelics research company Lobe Sciences, on Monday, called the move an “important step by a national government recognizing the value of these compounds in treating certain mental health conditions.”

“As we prepare for a (phase 2) study in Australia…it’s heartening to know that there is already significant support for psychedelic compound,” Young added.

Prescribing will be limited to psychiatrists permitted under the Authorised Prescriber Scheme by the TGA, following approval by a human research ethics committee. The guidance allows prescribing permissions to be granted under strict controls that ensure patient safety.

Adam Jackson

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.